The Union Budget 2025-26 introduces key healthcare measures, including the exemption of 36 life-saving drugs from Basic Customs Duty, the creation of daycare cancer centers in district hospitals, and ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal ...

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...

The company announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...

This Phase 1b/2, open-label, multicenter dose escalation and expansion combination study of ADG126 in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA ® ...